GALAPAGOS NV Business Summary

Galapagos NV (GLPG) is a clinical-stage biotechnology company that has transitioned into a lean, capital-allocation-driven platform following a massive strategic pivot in late 2025 to wind down its internal cell therapy operations. The company generates revenue primarily through high-value collaboration agreements—most notably its multi-year R&D alliance with Gilead Sciences—alongside licensing fees, milestone payments, and residual product supply revenue from divested assets. Its business segments are now concentrated on the development of small molecule and biologic therapies for immunology and oncology, utilizing a "financial chassis" model where its ~€3 billion cash reserve is deployed toward transformative M&A and mid-stage asset acquisitions. Galapagos competes directly with specialized biotech firms such as Idorsia Pharmaceuticals, Zealand Pharma, and Coherus BioSciences, positioning itself as a well-capitalized acquirer and partner that leverages a decentralized manufacturing legacy to accelerate external innovation rather than relying on broad internal discovery. Originally founded in 1999 by Onno van de Stolpe and Paul Stoffels, the company is currently led by CEO Henry Gosebruch, a prominent former AbbVie executive known for orchestrating the $63 billion Allergan acquisition. The leadership team was further bolstered in 2025 and early 2026 with the appointments of CFO Aaron Cox, previously of Horizon Therapeutics, and Chief Business Officer Sooin Kwon, both of whom bring deep M&A and deal-making pedigree to support the company’s new strategic direction. The Board of Directors is chaired by Jérôme Contamine and includes notable members such as Dr. Paulo Fontoura (Chief Medical Officer at Xaira) and Devang Bhuva, representing major stakeholder Gilead Sciences. Gilead remains the company's most significant institutional investor and strategic partner, maintaining a substantial equity stake and a seat on the board to oversee the deployment of Galapagos’ significant capital reserves.